SEC Tracker
Get the app
EDSA · XBRL financial data

Edesa Biotech financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (EDSA's year ends in late September)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development953*7041,176897104*1,0204849391,226*1,1252,7673,958
General and administrative1,416*1,1531,0441,035901*8791,1559651,245*1,2171,5301,562
Operating income (loss)(2,370)*(1,857)(2,220)(1,932)(1,004)*(1,899)(1,639)(1,904)(2,470)*(2,341)(4,297)(5,520)
Income tax expense (benefit)0*—100*—100*—10
Net income (loss)(1,720)*(1,678)(1,861)(1,668)(962)*(1,617)(1,590)(1,749)(2,228)*(2,248)(4,218)(5,408)
Earnings per share, basic USD per share—(0.54)(0.58)(0.52)(0.30)*(0.48)(0.30)(0.25)—(0.28)(0.49)(0.60)
Weighted average shares, basic thousands of shares—3,1283,1933,2223,247*3,3455,3067,0237,040*7,9738,5419,007
  • † Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (EDSA's year ends in late September)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents5,4004,2682,8002,0411,0001,60013,90012,40010,80012,10010,00010,300
Prepaid and other current assets44940533045536715810811378234198220
Total current assets6,4375,4164,2423,0471,6762,07214,38712,76111,51312,71710,41810,780
Property and equipment, net98700———————
Right-of-use asset91755536180000———
Total assets8,8907,8326,4755,2283,8144,16416,45414,80513,53114,71012,38512,721
Total current liabilities1,8221,9872,1512,3611,8331,9009156731,0797562,1883,910
Lease liability, non-current200000———————
Total liabilities1,8421,9872,1512,3611,833———————
Accumulated deficit(52,419)(54,097)(55,959)(57,627)(58,589)(60,232)(61,859)(63,645)(65,911)(68,196)(72,451)(77,896)
Total stockholders' equity7,0495,8454,3242,8671,9812,26415,54014,13212,45213,95410,1978,811
Total liabilities and equity8,8907,8326,4755,2283,8144,16416,45414,80513,53114,71012,38512,721
Common shares outstanding (cover page) thousands of shares3,1653,1723,2163,2473,4686,9367,0237,0388,3348,3488,8929,641
  • † Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (EDSA's year ends in late September)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(1,720)*(1,678)(1,861)(1,668)(962)*(1,617)(1,590)(1,749)(2,228)*(2,248)(4,218)(5,408)
Stock-based compensation517*184150110*94*8167*177*404*400485*547*
Depreciation and amortization46*4545*51*44*4325*26*26*2526*26*
Net cash from operating activities(1,468)*(1,407)(1,660)*(856)*(967)*(1,517)(2,383)*(1,701)*(1,721)*(2,087)(2,017)*(3,083)*
Purchases of property and equipment0*———————————
Net cash from investing activities0*0——————————
Proceeds from issuing common stock484*315276*138*0*6276,870*0*221*3,4980*3,500*
Proceeds from issuing equityyear only30(30)*——1,500——————
Net cash from financing activities412*306212*106*(31)*2,07214,773*0*186*3,355(9)*3,447*
Net change in cash(1,096)*(1,094)(1,468)*(759)*(1,004)*52612,333*(1,535)*(1,570)*1,260(2,048)*329*
  • † Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Edesa Biotech10,300not reported(3,083)*9.6M3.3 quarters 10-QJun 30, 2026
GeoVax Labs3,143not reported(3,658)*7.4M0.9 quarters 10-QJun 30, 2026
Earth Science Tech6319,026707287.6M— 10-QJun 30, 2026
X4 Pharmaceuticals195,0952,400(20,788)*99.1M9.4 quarters 10-QJun 30, 2026
Akari Therapeutics7,694not reported(3,109)*155.8B2.5 quarters 10-QJun 30, 2026
Synergy CHC2925,493(2,045)14.9M0.1 quarters 10-QMar 31, 2026
ProPhase Labs201,011(78)*15.6M0.3 quarters 10-QJun 30, 2026
Pluri3,529335*(4,443)*12.3M0.8 quarters 10-KJun 30, 2026
Cellectar Biosciences33,994not reported(6,010)*9.5M5.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.